Table 4.

Relative changes (Δ%) in penile erectile function from baseline (T0) to 90 days (T1) in l-arginine and placebo groups in the overall cohort, and in the subgroups of patients with baseline mild–moderate or severe vasculogenic ED, assessed at dynamic PDU

	Δ% (T1–T0/T0) l-Arginine	Δ%(T1–T0/T0) Placebo	p value
Overall cohort IIEF-6 score	20 (11 to 33.1)	0 (− 5.9 to 5.3)	< 0.0001
Overall cohort PSV (cm/s)	13.8 (− 0.2 to 25.4)	0 (− 2.8 to 5.1)	< 0.0001
Mild–moderate vasculogenic ED subgroup IIEF-6 score	19.5 (14.5 to 31.8)	0 (− 4.9 to 5.3)	< 0.0001
Mild–moderate vasculogenic ED subgroup PSV (cm/s)	23.4 (13.7 to 28.5)	0 (− 2.9 to 5)	< 0.0001
Severe vasculogenic ED subgroup IIEF-6 score	20 (− 6.3 to 42.5)	0 (− 11.8 to 6.3)	0.013
Severe vasculogenic ED subgroup PSV (cm/s)	− 4 (− 8 to 3.1)	0 (− 2.6 to 5.3)	NS

	Δ%(T1–T0/T0) l-Arginine Mild–moderate vasculogenic ED subgroup	Δ%(T1–T0/T0) l-Arginine Severe vasculogenic ED subgroup	p value
IIEF-6 score	19.5 (14.5–31.8)	20 (− 6.3 to 42.5)	NS
PSV (cm/s)	23.4 (13.7–28.5)	− 4 (− 8 to 3.1)	< 0.0001

Values expressed as median with interquartile range (25°–75° centiles)

PSV cavernous arteries peak systolic flow velocity